Compare
Precigen, Inc. vs Prothena Corp Public Ltd Co vs International Stem Cell Corp vs Roivant Sciences Ltd.
| Latest fiscal year | Precigen, Inc. PGEN | Prothena Corp Public Ltd Co PRTA | International Stem Cell Corp ISCO | Roivant Sciences Ltd. ROIV |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | $9.68M | $9.68M | $9.10M | $8.26M |
| Revenue growth (YoY) | +146.7% | -92.8% | +0.2% | -71.6% |
| Gross margin | n/a | n/a | 55.7% (computed) | n/a |
| Operating margin | n/m | n/m | -2.9% | n/m |
| Net margin | n/m | n/m | -4.6% | n/m |
| Net income | -$250.64M | -$244.09M | -$418.0K | -$299.77M |
| EPS (Diluted) | -$1.37 | -$4.53 | -$0.05 | -$0.54 |
| Operating cash flow | -$87.83M | -$163.58M | $8.0K | -$750.35M |
| Free cash flow | -$89.83M | n/a | -$35.0K | -$758.56M |
| Cash & equivalents | $30.23M | $307.53M | n/a | $1.42B |
| Total assets | $155.50M | $326.80M | $4.82M | $5.71B |
| Total liabilities | $134.59M | $46.33M | $4.58M | $416.27M |
| Shareholders' equity | $20.91M | $280.47M | -$4.06M | $4.53B |
| Return on year-end equity | n/m | -87.0% | n/a | -6.6% |
| Shares outstanding | 353.91M | 53.83M | 8.00M | 720.35M |
Revenue, most recent five fiscal years
| Fiscal year | Precigen, Inc. | Prothena Corp Public Ltd Co | International Stem Cell Corp | Roivant Sciences Ltd. |
|---|---|---|---|---|
| Latest | $9.68M Ended 2025-12-31 | $9.68M Ended 2025-12-31 | $9.10M Ended 2025-12-31 | $8.26M Ended 2026-03-31 |
| 1 year earlier | $3.92M Ended 2024-12-31 | $135.16M Ended 2024-12-31 | $9.09M Ended 2024-12-31 | $29.05M Ended 2025-03-31 |
| 2 years earlier | $6.22M Ended 2023-12-31 | $91.37M Ended 2023-12-31 | $7.79M Ended 2023-12-31 | $32.71M Ended 2024-03-31 |
| 3 years earlier | $26.91M Ended 2022-12-31 | $53.91M Ended 2022-12-31 | $8.18M Ended 2022-12-31 | $31.53M Ended 2023-03-31 |
| 4 years earlier | $14.27M Ended 2021-12-31 | $200.58M Ended 2021-12-31 | $7.18M Ended 2021-12-31 | $55.29M Ended 2022-03-31 |